**District Director** 

District Office

U.S Food and Drug Administration

Subject: Response to

issued to

on

Dear

On , U.S Food and Drug Administration (FDA) Investigators concluded their inspection of (FEI number: - hereafter referred to as ) located in . Following this inspection, we received the inspection observations documented on Form 483.

This letter serves as our initial response to the observations noted in the Form 483. We acknowledge the importance of these findings and are committed to addressing them thoroughly. We will provide a comprehensive supplemental update to the FDA on or before , followed by updates to keep you infor-med of our progress.

We take the observations seriously and are dedicated to implementing all necessary corrective actions to ensure that our systems comply with FDA regulations and that our products remain safe and effective. In addition to addressing the specific items listed in Form 483, we are actively working to identify and resolve any systemic issues that may have contributed to these observations.

If you have any questions or need any clarification, please do not hesitate to contact me at

Sincerely,



## Response to FDA 483 observations

This section lists observations, including actions that have been taken immediately, and planned actions.

Note: Copy each observation from Form 483 verbatim, including any annotation. Give detailed responses to each observation. Report your approach to addressing the observations and outline any overarching corrective actions or quality system improvements.

Note: Copy each observation from Form 483 verbatim, including any annotation.



#### FDA Observation No 1-

Copy observation No. 1 from Form 483/Warning Letter verbatim, including any annotation.

### Response:

Include a detailed response to the observation. Restate the issue clearly to demonstrate understanding. Provide a clear explanation and evidence to support your position.

## Root cause analysis:

Indicate the root cause of the issue. Include any analysis conducted to understand underlying issues that may have contributed to the observation. If the root cause analysis has not been completed, indicate your commitment to continue the investigation.

#### Corrective actions Obs. No 1:

Explain how the company plans to fix the issue.

**Immediate actions taken**: Provide a list and explanation of the immediate corrective actions completed. Provide dates for completed actions and make reference to the evidence in the attachments.

**Planned actions:** Outline steps your company is taking to address the issue systematically. Include a timeline for completing planned actions. Preventive actions: List and explain the long-term actions to prevent recurrence. Include a timeline for completing planned actions.

FDA Observation No [X]:
Corrective actions Obs. No [X]:

Note: Describe the methods for verifying the effectiveness of all actions.



# **Final discussions**

**Attachments** 

